Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889174 | PMC |
http://dx.doi.org/10.1038/s44184-025-00118-w | DOI Listing |
Int Ophthalmol
March 2025
Burapha University Hospital, Burapha University, Saen Suk, Chonburi, Thailand.
Background: Retinitis pigmentosa (RP) is a retinal dystrophy and genetically heterogeneous group that causes vision loss and necessitates innovative therapeutic strategies, and mesenchymal stem cell (MSC) therapy has shown potential due to its regenerative and immunomodulatory properties. This meta-analysis aims to evaluate the efficacy and safety of MSC therapies in improving visual outcomes, focusing on the impact of various MSC types, administration methods, and duration of benefits.
Methods: A systematic search of peer-reviewed studies was conducted to identify clinical trials and observational studies investigating MSC therapies for retinal conditions.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!